E. Jabbari

发表

Serum neurofilament light as a biomarker for prognosis in patients with newly diagnosed Parkinson disease

R. Barker, Y. Ben-Shlomo, T. Foltynie, 2021, medRxiv.

Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

Timothy A. Miller, Jennifer E. Phillips-Cremins, Lilah M. Besser, 2020, Neuron.

The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy

N. Williams, A. Lees, T. Révész, 2019, Movement disorders : official journal of the Movement Disorder Society.

A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism

H. Morris, I. Djoukhadar, F. Roncaroli, 2022, Neuropathology : official journal of the Japanese Society of Neuropathology.

Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes

J. E. Iglesias, D. Thomas, M. Bocchetta, 2019, Journal of movement disorders.

MAPT p.V363I mutation

Sonja W. Scholz, J. Troncoso, P. Pástor, 2019, Neurology: Genetics.

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

K. Duff, E. Jabbari, 2021, Nature Medicine.

Combining biomarkers for prognostic modelling of Parkinson’s disease

R. Barker, Y. Ben-Shlomo, H. Zetterberg, 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

Genome-wide determinants of mortality and clinical progression in Parkinson's disease

M. Nalls, H. Iwaki, C. Blauwendraat, 2022, medRxiv.

Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.

Timothy A. Miller, Sonja W. Scholz, Jennifer E. Phillips-Cremins, 2020, Neuron.

MAPT p.V363I mutation A rare cause of corticobasal degeneration

Sonja W. Scholz, C. Morris, J. Troncoso, 2022 .

The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation

L. Sekaran, E. Jabbari, S. Sethuraman, 2014, BMJ Case Reports.

Longitudinally extensive transverse myelitis: a rare association with common variable immunodeficiency

C. Marshall, H. Longhurst, R. Sylvester, 2014, Practical Neurology.

Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease

M. Nalls, A. Singleton, H. Iwaki, 2020, medRxiv.

Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates

J. Attems, J. Hedreen, D. Mann, 2020, Acta Neuropathologica.

Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype

J. Hardy, S. Al-Sarraj, A. Lees, 2018, bioRxiv.

Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study

Sonja W. Scholz, C. Blauwendraat, M. Cookson, 2020, The Lancet Neurology.

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes

J. Rowe, T. Foltynie, A. Lees, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome

J. Klein, J. Rowe, N. Williams, 2019, JAMA neurology.

Chronic effects of inflammation on tauopathies

J. Hardy, M. Thom, K. Duff, 2023, The Lancet Neurology.

The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation.

A. Lang, G. Stebbins, A. Boxer, 2020, Parkinsonism & related disorders.

A rare cause of corticobasal degeneration

Sonja W. Scholz, C. Morris, J. Troncoso, 2022 .

Neurofilament light levels predict clinical progression and death in multiple system atrophy

O. Rascol, D. Burn, P. Leigh, 2022, Brain : a journal of neurology.

Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers

H. Zetterberg, H. Morris, E. Jabbari, 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

Common variation at the LRRK2 locus is associated with survival in the primary tauopathy progressive supranuclear palsy

Sonja W. Scholz, M. Cookson, J. Hardy, 2020, bioRxiv.

Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials

J. Klein, D. Burn, T. Rittman, 2023, Brain : a journal of neurology.

MAPT ‐Associated Familial Progressive Supranuclear Palsy with Typical Corticobasal Degeneration Neuropathology: A Clinicopathological Report

T. Révész, J. Rohrer, H. Morris, 2023, Movement disorders clinical practice.

MAPT p.V363I mutation

Sonja W. Scholz, J. Troncoso, P. Pástor, 2019, Neurology: Genetics.

Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative

M. Burnell, P. Piccini, A. Jha, 2023, Journal of Parkinson's disease.

Genome-wide determinants of mortality and motor progression in Parkinson’s disease

H. Iwaki, C. Blauwendraat, M. Shoai, 2024, NPJ Parkinson's disease.

Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia

H. Leonard, D. Knopman, C. van Broeckhoven, 2024, American journal of human genetics.